Evidence map›Paper›PMID 40327064›Full record

ReviewDermatologie (Heidelberg, Germany)2025

[Novel foods-What must be considered?]

Frédéric Toussaint, Nicola Wagner

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Frédéric ToussaintHautklinik, Uniklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland.
Nicola WagnerHautklinik, Uniklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland. Nicola.Wagner@uk-erlangen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel foods are food products that were not in circulation for consumption to any significant extent in the European Union before 1997. The introduction of novel foods harbors the risk of allergic reactions to new allergens or new cross-reactions that need to be taken into account. The aim of the study is to highlight the allergenic potential of selected novel foods. Allergens in edible insects in particular harbor the risk of anaphylactic reactions. In western industrial nations cross-sensitivity to crustaceans and shellfish are likely to play an important role in the future. Chia seeds, which are rich in fiber and omega-3-fatty acids, are also embraced in the term novel foods. Cross-reactions to sesame seeds or to other labiates (mustard, thyme, rosemary, sage) are possible. Consumption of natto, a Japanese dish containing fermented soy beans, can lead to delayed anaphylaxis. Nattokinase as well as polyglutamic acid (PGA) are well-known triggering allergens. It is postulated that sensitization to PGA may be acquired from skin contact to jellyfish and potentially by cosmetics containing PGA.

Indexed as

AllergensFood HypersensitivityAnaphylaxisAnimalsCross ReactionsHumansAllergensAllergyChia seedsCross-reactionsEdible insectsNatto

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.